

Sister Study Self-Reported and Medically Confirmed Cancer Estimates by Primary Site of Origin, Excluding Non-Melanoma Skin Cancer

Table 1: Data Release 9.1^{1,2}

	Prevalent		Unknown Timing		Incident				Total Incident
	Diagnosis at or prior to baseline	Diagnosis date unknown	Not confirmed (Self-report without medical, NDI, or death certificate confirmation)		Confirmed by NDI or Death Certificate only (No medical confirmation)		Medically Confirmed		
	N	N	N	%	N	%	N	%	N
Any Cancer (excluding NMSC)	4,448	248	1,984	27.5	312	4.3	4,925	68.2	7,221
Primary Site³									
Breast Cancer									
DCIS or invasive	57	22	730	18.3	45	1.1	3,224	80.6	3,999
LCIS	54	9	38	30.2	0	0.0	88	69.8	126
Reproductive Cancers									
Ovarian, fallopian tube, and peritoneal	202	25	73	25.9	37	13.1	172	61.0	282
Uterine (including endometrial)	380	59	126	31.7	20	5.0	251	63.2	397
Cervical	544	12	20	46.5	1	2.3	22	51.2	43
Vulvar	20	2	9	26.5	0	0.0	25	73.5	34
Vaginal	7	2	4	66.7	0	0.0	2	33.3	6
Digestive Cancers									
Colon and rectal (including appendiceal)	203	15	133	41.2	23	7.1	167	51.7	323
Small intestinal	5	0	3	33.3	3	33.3	3	33.3	9
Anal	8	0	11	36.7	1	3.3	18	60.0	30
Pancreatic	8	1	34	18.7	83	45.6	65	35.7	182
Biliary tract ⁴	1	0	4	10.5	15	39.5	19	50.0	38
Liver (including intrahepatic bile duct) ⁴	7	0	31	50.8	20	32.8	10	16.4	61
Stomach and esophageal	15	1	18	33.3	19	35.2	17	31.5	54
Endocrine Gland Cancers									
Thyroid	275	18	91	33.3	1	0.4	181	66.3	273
Lower Respiratory and Intrathoracic Cancers									
Bronchus and lung	63	12	174	33.1	148	28.1	204	38.8	526
Head and Neck Cancers									
Lip, oral cavity, pharynx, and upper respiratory tract	22	2	29	33.7	8	9.3	49	57.0	86

Abbreviations: DCIS=Ductal carcinoma *in situ*; LCIS=Lobular carcinoma *in situ*; NMSC=non-melanoma skin cancer

¹ Data release 9.1 includes events from follow-up phases that closed on or before 9/30/2019, excluding all data from participants who have withdrawn their data from the study (n=3)

² See Table 2 for approximated estimates for additional cancer outcomes

³ Includes all cancers that display invasive behavior (ICD-O-3 behavior code = /3), *in situ* behavior (ICD-O-3 behavior code = /2), or uncertain or borderline behavior (ICD-O-3 behavior code = /1). See specific ICD10 codes for each cancer type [here](#)

⁴ Intrahepatic bile duct cancer diagnoses are included in both biliary tract and liver cancer counts

Table 2: Approximates Data Release 9.1^{1,2}

Primary Site ³	Prevalent		Unknown Timing		Incident				Total Incident
	Diagnosis at or prior to baseline	Diagnosis date unknown	Not confirmed (Self-report without medical, NDI, or death certificate confirmation)		Confirmed by NDI or Death Certificate only (No medical confirmation)		Medically Confirmed		
			N	%	N	%	N	%	
Urinary Cancers									
Bladder	61	1	29	24.0	6	5.0	86	71.1	121
Kidney	59	1	47	30.9	8	5.3	97	63.8	152
Renal pelvis, ureter, urethra	2	0	4	21.1	3	15.8	12	63.2	19
Skin Cancers									
Melanoma of the skin	746	57	405	43.6	4	0.4	520	56.0	929
Lymphoid and Hematopoietic Cancers									
Non-Hodgkin's lymphoma	90	7	90	31.7	17	6.0	177	62.3	284
Hodgkin's lymphoma	28	10	14	63.6	3	13.6	5	22.7	22
Multiple myeloma	6	1	28	29.2	13	13.5	55	57.3	96
Leukemia	55	11	77	35.5	20	9.2	120	55.3	217
Myelodysplastic syndrome	2	3	15	45.5	7	21.2	11	33.3	33
Polycythemia vera	3	0	12	60.0	0	0.0	8	40.0	20
Brain and Other Central Nervous System Cancers									
Brain tumors (malignant and benign)	53	30	170	46.3	39	10.6	158	43.1	367
Eye and adnexa	9	2	8	80.0	0	0.0	2	20.0	10
Other central nervous system	1	3	7	100.0	0	0.0	0	0.0	7
Other and Unspecified Cancers									
Bone	13	1	41	85.4	2	4.2	5	10.4	48
Mesothelium and soft tissue	20	6	14	29.8	12	25.5	21	44.7	47
Gastrointestinal stromal tumor	3	2	8	36.4	0	0.0	14	63.6	22
Neuroendocrine	20	2	20	27.0	1	1.4	53	71.6	74
Any other cancer, specified or unspecified (excluding NMSC)	81	522	138	52.7	38	14.5	86	32.8	262

Abbreviation: NMSC=non-melanoma skin cancer

¹ Data release 9.1 includes events from follow-up phases that closed on or before 9/30/2019, excluding all data from participants who have withdrawn their data from the study (n=3)

² These baseline and self-reported estimates are likely an over-estimate of the actual number of cases

³ Includes all cancers that display invasive behavior (ICD-O-3 behavior code = /3), *in situ* behavior (ICD-O-3 behavior code = /2), or uncertain or borderline behavior (ICD-O-3 behavior code = /1). See specific ICD10 codes for each cancer type [here](#)